27 July 2026 | 5:00AM EDT Equity Research Vertex Pharmaceuticals Inc. (VRTX): 2Q earnings preview: Facing an eventful 2H VRTX shares have underperformed the sector and broader market YTD (-5% vs. DRG, vs. -2% vs. S&P 500), as SION's likely August Phase 2 data in cystic fibrosis (CF; evaluating an add-on to VRTX's standard-of-care Trikafta) has served as an overhang. While SION has framed the bar-for-success as a 10mmol/L reduction on key biomarker sweat chloride (SwCl), for VRTX shares the bar is higher and ...